• Ascentage Pharma's lisaftoclax received China's breakthrough therapy designation with acalabrutinib for previously untreated adults with chronic lymphocytic leukemia/small lymphocytic lymphoma.
• The designation provides priority regulatory guidance to accelerate development, with potential eligibility for priority review and conditional approval.
• The combination is being evaluated as a first-line treatment in GLORA-2, an ongoing global Phase III registration trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610201930PRIMZONEFULLFEED9849644) on October 20, 2026, and is solely responsible for the information contained therein.